Tiny player picks up $30M to go after CAR-T's biggest challenges
Of all the challenges associated with reengineering CAR-T therapies — which have been wildly successful in treating certain blood cancers — to attack solid tumors, toxicity often ranks near the top.
“If there is no therapeutic window, the trial will be terminated,” Simone Song, founder and managing partner at ORI Capital, told Endpoints News.
It was the reason why ORI, a Hong Kong-based healthcare VC firm focused on cancer, metabolic disorders and neurodegenerative diseases, decided to incubate a startup by the name of AffyImmune back in 2017. And it’s why Song’s team is handing over another $30 million to fund a first-in-human trial that kicked off late last year and send a second CAR-T therapy into the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.